Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Rev Vaccines. 2002 Jun;1(1):65-74.

Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine.

Author information

  • Division of Research, Kaiser Permanente, Oakland, CA 94612-2304, USA. tom.ray@kp.org

Abstract

In February 2000, a pneumococcal conjugate vaccine was licensed for use in the USA. This vaccine has been shown to be effective in reducing pneumococcal disease, and has been recommended for universal use in infants. However, pneumococcal conjugate vaccine is by far the most expensive child vaccine series routinely administered in the USA, alone accounting for over 40% of the total purchase price of vaccines for the recommended childhood schedule. This article reviews the existing efficacy and economic studies of pneumococcal conjugate vaccine and discusses the process by which routine use of pneumococcal conjugate vaccine was introduced and the role economic analysis played in that process. Some of the scientific and funding issues relating to its use in both the industrialized and developing world are also discussed.

PMID:
12908513
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk